Effect of nisoldipine on red cell deformability and platelet aggregation in stroke patients.
Reduced red cell deformability and increased platelet aggregability are assumed to contribute to various ischemic diseases, and it has been postulated that these abnormalities may be improved by drug treatment. In this study, the effect of nisoldipine (Bay K 5552, CAS 63675-72-9) on red cell deformability and platelet aggregation in patients with chronic ischemic cerebrovascular disease and hypertension was examined. Administration of nisoldipine for 4 weeks caused a significant improvement of red cell deformability and platelet aggregability without causing any adverse effects.